Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Shilpa Medicare gets USFDA approval for Imatinib Mesylate Tablets

      Shilpa Medicare gets USFDA approval for Imatinib Mesylate Tablets

      Farhat Nasim21 Jan 2019 9:30 AM IST
      Imatinib Mesylate is a generic equivalent of the reference-listed drug (RLD) Gleevec (100mg and 400mg), which is used in the treatment of leukaemia as...
      Lilly Lartruvo fails key trial, will no longer be prescribed

      Lilly Lartruvo fails key trial, will no longer be prescribed

      Farhat Nasim21 Jan 2019 9:15 AM IST
      Lartruvo will continue to be available to patients who appear to be benefiting from it as global regulators determine the next steps for the...
      Major Relief- No Sales Tax on drugs, implants consumables used treatment says Kerala HC

      Major Relief- No Sales Tax on drugs, implants consumables used treatment says Kerala HC

      Farhat Nasim19 Jan 2019 12:43 PM IST
      Kochi: In a major relief to the healthcare services in the state, the Kerela High Court in a landmark judgement has held that drugs, implants and...
      Immunomedics sacituzumab fails to win accelerated approval from the FDA

      Immunomedics sacituzumab fails to win accelerated approval from the FDA

      Farhat Nasim19 Jan 2019 9:00 AM IST
      "The issues related to approvability in the CRL (complete response letter) were exclusively focused on Chemistry, Manufacturing and Control matters...
      80 more Fixed Dose Drugs including Antibiotics, Hypertension Combos Banned by Health Ministry

      80 more Fixed Dose Drugs including Antibiotics, Hypertension Combos Banned by Health Ministry

      Farhat Nasim18 Jan 2019 10:59 AM IST
      According to the notification, some of the fixed dose combination drugs that have been banned include antibiotics like Cefglobe OZ, Taxim -OZ, drugs...
      Zydus receives final approval from the USFDA for Acetazolamide ER Capsules

      Zydus receives final approval from the USFDA for Acetazolamide ER Capsules

      Farhat Nasim18 Jan 2019 10:00 AM IST
      Acetazolamide is a potent carbonic anhydrase inhibitor. Acetazolamide ER capsules are used to treat certain types of glaucoma (caused by increased...
      Suven Life Sciences secures Product Patents in Australia and Singapore

      Suven Life Sciences secures Product Patents in Australia and Singapore

      Farhat Nasim18 Jan 2019 9:30 AM IST
      "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that is being developed for cognitive disorders...
      Exelixis gets USFDA approval to CABOMETYX tablets for previously treated HCC

      Exelixis gets USFDA approval to CABOMETYX tablets for previously treated HCC

      Farhat Nasim18 Jan 2019 9:15 AM IST
      CABOMETYX tablets are approved in the United States for the treatment of patients with advanced renal cell carcinoma (RCC) and for the treatment of...
      Reckitt Benckiser chief Rakesh Kapoor to step down

      Reckitt Benckiser chief Rakesh Kapoor to step down

      Farhat Nasim18 Jan 2019 9:00 AM IST
      One of UK's highest-paid CEOs Rakesh Kapoor will leave Reckitt Benckiser by end of 2019.New Delhi: British FMCG major Reckitt Benckiser (RB) Wednesday...
      HC Relief to Reckitt Benckiser in advertisement of ASU drugs case

      HC Relief to Reckitt Benckiser in advertisement of ASU drugs case

      Farhat Nasim17 Jan 2019 5:36 PM IST
      New Delhi: Reckitt Benckiser, over a decade long market player in the health, hygiene and home consumer goods has been smoothly commercialising its...
      Fortis Healthcare to take Rs 1100 crore loan from Citibank

      Fortis Healthcare to take Rs 1100 crore loan from Citibank

      Farhat Nasim17 Jan 2019 11:37 AM IST
      The board of Fortis Healthcare had approved in July last year a proposal from IHH Healthcare to invest Rs 4,000 crore by way of preferential allotment...
      Abbott to acquire mitral valve device maker Cephea Valve Technologies

      Abbott to acquire mitral valve device maker Cephea Valve Technologies

      Farhat Nasim17 Jan 2019 9:30 AM IST
      "The acquisition of Cephea builds on Abbott's strong position in structural heart therapies and is consistent with our strategy to develop...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok